M

Mersana Therapeutics
D

MRSN

2.03500
USD
0.05
(2.52%)
Market Closed
Volume
17,014
EPS
-2
Div Yield
-
P/E
-3
Market Cap
251,389,470
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    65.635 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    748 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    SYK
    SYK
    6.90
    (1.80%)
    384.88 USD
    More
News

Title: Mersana Therapeutics

Sector: Healthcare
Industry: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.